Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab resistance is needed. In order to identify mechanisms...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2013-02-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/31.pdf |